Reclassifying high-risk primary prevention: real-world LDL-C reduction with bempedoic acid in a multimorbid rural population

24 April 2026 (11:00 - 11:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Carl Deaney

Louth (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Urate dynamics, gout events, and tolerability of bempedoic acid for primary ASCVD prevention: a real-world retrospective review from rural primary care in England

Mrs M. Donaldson (Louth, GB)

Abstract Slides

Presentation thumbnail

Impact of revised 2025 ESC/EAS guidelines for the management of dyslipidaemias in the community

Doctor N. Ahanchi (Fribourg, CH)

Abstract Slides

Presentation thumbnail

Nurse-led secondary prevention lipid clinic

Mr A. Young (Bournemouth, GB)

Abstract Slides

Presentation thumbnail

Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis

Associate Professor E. Begic (Sarajevo, BA)

Abstract Slides

Presentation thumbnail

Low density lipoprotein-Cholesterol levels evaluation in the total population and subgroup of non-diabetic dyslipidemic Greek patients of ZEUS study under fixed-dose-combination ezetimibe/rosuvastatin

Mr G. Tsioumas (Athens, GR)

Abstract Slides

Access the full session

Session thumbnail

Achieving lipid goals in the real world (1)

The Event

Event poster

ESC Preventive Cardiology 2026

24 April 2026 11:00 CET

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

Risk assessment and lipid management in primary prevention

Congress Presentation

Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources